{"id":6992,"date":"2026-04-23T06:49:51","date_gmt":"2026-04-23T04:49:51","guid":{"rendered":"https:\/\/mediconomics.com\/?post_type=glossary&#038;p=6992"},"modified":"2026-07-13T19:09:47","modified_gmt":"2026-07-13T17:09:47","slug":"bayesian-statistics","status":"publish","type":"glossary","link":"https:\/\/mediconomics.com\/en\/glossar\/bayesian-statistics\/","title":{"rendered":"Bayesian Statistics"},"content":{"rendered":"<p>Bayesian statistics is an approach to inference in which probabilities are interpreted as a degree of belief. Existing prior knowledge (the prior) is combined with new study data via the likelihood, yielding an updated distribution (the posterior), from which estimates and uncertainties can be derived. In clinical trials, Bayesian statistics is frequently used to steer decisions adaptively and to update evidence consistently across interim analyses.<\/p>\n<h2>Basic principles: prior, likelihood and posterior<\/h2>\n<p>Unlike frequentist statistics, which treats parameters as fixed (unknown) quantities and locates randomness solely in the data, Bayesian statistics treats the parameters themselves as random variables. The core is Bayes&#8217; theorem, by which a prior assumption about a parameter (e.g. the expected response rate) is converted, through observations from the trial, into a posterior distribution.<\/p>\n<ul>\n<li><strong>Prior distribution:<\/strong> represents prior knowledge, e.g. from preclinical data, Phase I\/II results or external real-world evidence sources.<\/li>\n<li><strong>Likelihood:<\/strong> describes how probable the observed data would be given a particular parameter value.<\/li>\n<li><strong>Posterior distribution:<\/strong> combines the prior and likelihood; from this, for example, probabilities for clinically relevant effects can be calculated directly.<\/li>\n<\/ul>\n<p>In practice, this means that instead of a p-value, statements such as &#8220;the probability that the treatment exceeds the clinically relevant effect is 92%&#8221; are often reported. Such statements are frequently more intuitive for decision-making processes in development programmes than significance tests.<\/p>\n<h2>Applications in clinical development and study design<\/h2>\n<p>Bayesian statistics is used in drug and medical device development in particular when decisions are to be made during the course of the study or when external evidence can meaningfully be incorporated. Typical applications include adaptive designs, dose-finding, early feasibility studies and situations with small sample sizes, for example in orphan drug development.<\/p>\n<ul>\n<li><strong>Adaptive randomisation:<\/strong> treatment arms can be weighted in favour of better-performing options, provided this is predefined in the clinical study protocol and the statistical methodology.<\/li>\n<li><strong>Futility and success criteria:<\/strong> early termination in the case of low probability of success, or accelerated continuation in the case of high posterior probability.<\/li>\n<li><strong>Borrowing external data:<\/strong> use of historical controls or registry data with robust models (e.g. hierarchical priors) to limit bias.<\/li>\n<\/ul>\n<p>For endpoints such as progression-free survival or overall survival, Bayesian models can likewise be applied, for example to derive hazard ratio distributions or posterior predictive probabilities of study success. It is important that model assumptions are transparently documented and that sensitivity analyses (e.g. alternative priors) are planned.<\/p>\n<h2>Interpretation, uncertainty and communication<\/h2>\n<p>An advantage of Bayesian statistics is the direct interpretability of uncertainty. Confidence intervals are replaced by <em>credible intervals<\/em>, which can be understood as probability intervals. Communication should nevertheless be handled carefully, because stakeholders are often accustomed to p-values and classical significance thresholds.<\/p>\n<p>For authorities and ethics committees, it is essential that decision rules are set in advance to avoid inflation of error probabilities. This includes clearly defined interim analysis time points, stopping criteria and a traceable approach to controlling operational bias risks, for example through independent bodies such as a Data Safety Monitoring Board.<\/p>\n<h2>Methodological and regulatory aspects (EU\/Germany focus)<\/h2>\n<p>Bayesian methods are, in principle, permitted in Europe but require particularly precise statistical planning and documentation. In application documents (e.g. a Clinical Trial Application), it should be clearly described why a Bayesian approach was chosen, how the prior is justified, and how sensitivity analyses test robustness. For medical devices, the incorporation of external evidence can become relevant in the context of a clinical evaluation or a Post-Market Clinical Follow-up, provided data quality and comparability are demonstrated.<\/p>\n<p>At the operational level, additional requirements arise for data management and monitoring: interim analyses require clean data processes (e.g. Electronic Data Capture, query management, database lock per interim cut) and clear roles (sponsor, principal investigator, biostatistics). Sources of error include, among others, overly optimistic priors, unclear stopping rules, or the mixing of exploratory and confirmatory objectives.<\/p>\n<h2>Significance for clinical trials<\/h2>\n<p>For sponsor and CRO, Bayesian statistics can bring efficiency gains: decisions can be made earlier, resources can be deployed more specifically, and uncertainties are explicitly quantified. At the same time, the need for careful prospective planning, traceable programming (e.g. validated statistical scripts) and clear governance structures increases. Full-service CROs such as mediconomics typically support the preparation of the statistical analysis plan, coordination with authorities, and the implementation of interim analyses along defined Standard Operating Procedure processes.<\/p>\n<h2>Frequently Asked Questions (FAQ) and regulatory references<\/h2>\n<h3>Is Bayesian statistics accepted in pivotal trials?<\/h3>\n<p>In principle, yes, provided the methodology, prior justification and decision rules are prospectively defined and transparently documented. A Bayesian approach is often used in early phases or as a supplementary analysis; for confirmatory trials, close coordination with authorities is advisable.<\/p>\n<h3>What is the biggest difference from frequentist analysis?<\/h3>\n<p>Bayesian statistics provides probability statements about parameters or effects (the posterior), whereas frequentist tests provide statements about the data under a null hypothesis (the p-value). This changes the interpretation of uncertainty and the way decision boundaries are formulated.<\/p>\n<h3>What risks arise from the choice of prior?<\/h3>\n<p>An overly informative or poorly justified prior can bias results and reduce credibility. Sensitivity analyses, transparent derivation (e.g. from earlier studies) and, where appropriate, robust or weakly informative priors are therefore important components of good planning.<\/p>\n<ul>\n<li>ICH E9 (R1): statistical principles in clinical trials and addendum on estimands and sensitivity analyses.<\/li>\n<li>Regulation (EU) 536\/2014 (Clinical Trials Regulation): framework for the authorisation and conduct of clinical trials in the EU, including requirements for prospective planning and documentation.<\/li>\n<li>ICH E6 (R3): Good Clinical Practice; quality management and governance, relevant for data integrity and interim analyses.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Bayesian statistics is an approach to inference in which probabilities are interpreted as a degree of belief. Existing prior knowledge (the prior) is combined with new study data via the likelihood, yielding an updated distribution (the posterior), from which estimates and uncertainties can be derived. In clinical trials, Bayesian statistics is frequently used to steer [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6992","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6992\/revisions"}],"predecessor-version":[{"id":6995,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6992\/revisions\/6995"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6992"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}